Researchers
Researcher Citation Index
Researchers whose published work is referenced on Peptides Research Hub. Each profile is a factual citation index, listing the articles on this site that draw on their research. Researchers are not affiliated with Peptides Research Hub and have not authored or endorsed any content here.
A. Michael Lincoff, MD
Cleveland Clinic, Cleveland, Ohio
Interventional cardiologist and clinical trialist whose published work includes the design and conduct of large cardiovascular outcomes trials; principal investigator of the SELECT trial of semaglutide in obesity with established cardiovascular disease.
Cited in 0 articles
Ania M. Jastreboff, MD, PhD
Yale University School of Medicine
Endocrinologist and obesity medicine physician whose published research covers the neurobiology of obesity and the clinical pharmacology of incretin-based therapies.
Cited in 2 articles
Daniel J. Drucker, MD
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto
Internist and molecular endocrinologist whose foundational research established much of the contemporary understanding of glucagon-like peptide-1 biology and incretin therapeutics.
Cited in 9 articles
Donna H. Ryan, MD
Pennington Biomedical Research Center, Louisiana State University
Obesity medicine physician and clinical researcher whose published work covers lifestyle intervention, pharmacotherapy for obesity, and cardiovascular outcomes in weight management trials including SELECT.
Cited in 0 articles
Filip K. Knop, MD, PhD
University of Copenhagen, Center for Clinical Metabolic Research
Physician-scientist whose research addresses incretin physiology, the pathophysiology of type 2 diabetes, and the pharmacological development of GLP-1-based therapies.
Cited in 4 articles
John P.H. Wilding, DM
University of Liverpool, Institute of Life Course and Medical Sciences
Clinical endocrinologist and obesity researcher who led the STEP-1 pivotal trial of semaglutide 2.4 mg and has published extensively on pharmacological treatments for obesity.
Cited in 2 articles
Juan P. Frias, MD
Velocity Clinical Research, Los Angeles
Endocrinologist and clinical researcher whose published work spans phase II and phase III trials of incretin and dual incretin therapeutics for type 2 diabetes and obesity.
Cited in 2 articles
Juris J. Meier, MD
Ruhr University Bochum, St. Josef-Hospital
Diabetologist whose published work covers beta-cell biology, the incretin effect, and the comparative pharmacology of incretin-based therapies.
Cited in 4 articles
Michael A. Nauck, MD
Ruhr University Bochum, Diabetes Division, Bad Lauterberg im Harz
Diabetologist and endocrinologist whose research defined the incretin effect and its impairment in type 2 diabetes, and who contributed clinical trial leadership across the GLP-1 receptor agonist and oral semaglutide programs.
Cited in 0 articles
Predrag Sikiric, MD, PhD
University of Zagreb School of Medicine
Physician-scientist whose preclinical research program at the University of Zagreb has characterised the body protection compound and BPC-157 in rodent models of tissue injury, gastric ulcer, and organ protection.
Cited in 4 articles
Søren Madsbad, MD, DMSc
University of Copenhagen, Hvidovre Hospital
Endocrinologist whose published research focuses on the clinical pharmacology of GLP-1 receptor agonists and other incretin-based therapies in type 2 diabetes.
Cited in 9 articles
Steven P. Marso, MD
Research Medical Center, Kansas City, Missouri
Interventional cardiologist who led the LEADER cardiovascular outcomes trial for liraglutide and the SUSTAIN-6 trial for semaglutide, establishing cardiovascular benefit for GLP-1 receptor agonists.
Cited in 3 articles
Sven Seiwerth, MD, PhD
University of Zagreb School of Medicine
Pathologist at the University of Zagreb whose research has included histopathological and preclinical evaluation of BPC-157 effects on tissue regeneration and wound healing in animal models.
Cited in 4 articles
Tina Vilsbøll, MD, DMSc
Steno Diabetes Center Copenhagen
Clinical pharmacologist whose published work centers on the physiological role of GLP-1 and the clinical pharmacology of GLP-1 receptor agonists in type 2 diabetes and obesity.
Cited in 4 articles
Vanita R. Aroda, MD
Brigham and Women's Hospital, Harvard Medical School
Endocrinologist and clinical trialist whose published work includes leadership roles in multiple PIONEER oral semaglutide trials and other phase III programs in type 2 diabetes.
Cited in 0 articles